Trials / No Longer Available
No Longer AvailableNCT05483322
An Open-Label, Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia (FTD)
An Open-Label, Expanded Access Protocol of LAM-002A (Apilimod Dimeyslate Capsules), Administered to a Single Subject With C9ORF72-Associated Frontotemporal Dementia (FTD)
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- OrphAI Therapeutics · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This is an open-label, single subject, expanded access protocol (EAP) of the LAM-002A investigational product administered orally at 125 mg BID for 52 weeks.
Detailed description
LAM-002A will be provided for expanded access for an individual patient under 21 CFR 312.310. It will be administered BID orally at a dose of 125 mg. Assessment of safety will include clinical observations and monitoring following administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LAM-002A | 25mg capsules |
Timeline
- First posted
- 2022-08-02
- Last updated
- 2022-08-02
Source: ClinicalTrials.gov record NCT05483322. Inclusion in this directory is not an endorsement.